SLU-PP-332: A Literature Course in Six Modules

SLU-PP-332 is one of the most frequently discussed compounds in online "exercise mimetic" conversations, yet the published record behind it is small, entirely preclinical, and often described inaccurately. This course walks through that record module by module: what the compound is, how its mechanism is described, what each study actually measured, what the literature does and does not say about adverse events, what pharmacokinetic information exists, and where the compound sits in regulatory terms. Each module closes with the limits of the evidence, because the limits are a large part of the story.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here is a protocol, a recommendation, or a statement that any outcome would occur in a person.

Module 1: What SLU-PP-332 Is and How It Has Been Studied

Class and naming

Despite being catalogued alongside research peptides by hobbyist communities, SLU-PP-332 is a synthetic small molecule, not a peptide. It contains no amino acid chain. The literature classifies it as an agonist of the estrogen-related receptors (ERRs) — a family of three orphan nuclear receptors, ERRα (gene ESRRA), ERRβ, and ERRγ — and researchers described it as a pan-ERR agonist with activity across all three subtypes in the 2023 report titled "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity" (PMID 36988910).

The ERRs are not estrogen receptors, despite the name. They share sequence similarity with estrogen receptors but do not bind estrogens; they are transcription factors associated with mitochondrial and oxidative metabolism. Work published before any ERR agonist chemistry existed established ERRγ as a regulator of muscle mitochondrial activity and oxidative capacity (PMID 20418374), which is the biological premise later compounds were built on.

Origin and chemical series

SLU-PP-332 belongs to a laboratory-coded chemical series. A related molecule from the same series, SLU-PP-915, was later characterised as an orally active ERR agonist that enhanced aerobic exercise capacity (PMID 41421047), and additional pan-ERR agonists from this line of work were studied in cardiac models (PMID 37961903). ERRα agonist activity has also been mapped in large compound libraries independently of this series: researchers screened the Tox21 collection and identified ERRα agonists among the tested chemicals (PMID 29216352), illustrating that ERR agonism is a measurable pharmacological property with established assay systems.

How it has been studied

Every study in this verified set is preclinical — cell-based assays and rodent models. Endpoints included skeletal muscle gene expression and exercise capacity (PMID 36988910), features of metabolic syndrome (PMID 37739806), kidney mitochondrial function and inflammation in aging (PMID 37717940), and cardiac metabolism in heart failure (PMID 37961903).

Limits of the evidence in Module 1

• No human clinical trial of SLU-PP-332 appears in this verified literature.
• The verified record does not define a human dosage form, purity standard, or formulation.
• Material sold to laboratories under this name is not characterised in these papers; product identity and content are outside the published scope.

Module 2: Mechanism as Described in the Literature

Receptor engagement

The described mechanism is transcriptional. ERRs act as constitutively active nuclear receptors regulating genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. Researchers reported that a synthetic ERRα/β/γ agonist produced an acute transcriptional response in skeletal muscle resembling the response to aerobic exercise, and that this response was lost when ERRα was absent — making the effect ERRα-dependent in that model (PMID 36988910).

Downstream metabolic pathways

Tissue-level mechanisms described in the ERR literature differ by organ. In the heart, researchers attributed the effects of pan-ERR agonists to enhanced cardiac fatty acid metabolism and improved mitochondrial function (PMID 37961903). In the aging kidney, the study reported that ERR agonism reversed markers of mitochondrial dysfunction and inflammation (PMID 37717940). Receptor-level work in kidney disease independently linked ESRRA to ATG5-mediated mitophagy and arginine metabolism in a diabetic kidney disease model (PMID 41376268), which is mechanism for the receptor rather than for this specific compound.

Context: not the only nuclear-receptor approach

ERR agonism sits within a broader field of nuclear-receptor and receptor-targeted metabolic pharmacology. For comparison, a separate line of work reported that an FXR/TGR5 dual agonist prevented progression of nephropathy in models of diabetes and obesity (PMID 29089371). Different receptor, different compound — useful only as a reminder that "improves mitochondrial endpoints in a rodent model" is a common preclinical finding across many targets and does not, on its own, predict human outcomes.

Limits of the evidence in Module 2

• Mechanism described in rodent tissue and cell systems does not establish the same mechanism, potency, or tissue distribution in humans.
• Pan-agonism means all three ERR subtypes are engaged; the literature does not resolve which tissues dominate the net effect in an intact organism.
• Mechanistic plausibility is not evidence of clinical benefit.

Module 3: Reported Outcomes by Study

The table below summarises what each verified study examined and what researchers reported. Statements are limited to the published scope; no outcome listed here has been shown in humans.

Reading these results carefully

Three details matter when interpreting this set. First, several reports concern the broader pan-ERR agonist series rather than SLU-PP-332 alone, including the cardiac work (PMID 37961903) and the orally active analog study (PMID 41421047). Second, exercise-capacity findings were measured as animal performance endpoints in mice, not as training outcomes in people (PMID 36988910). Third, one muscle-atrophy report was explicitly labelled a pilot study by its authors (PMID 40692696), meaning it was designed for feasibility and signal generation rather than confirmation.

Limits of the evidence in Module 3

• All outcomes are animal or cell findings; none establishes efficacy in humans.
• Endpoints vary widely across studies (gene expression, treadmill performance, tissue markers), so results are not directly comparable.
• Publication of positive preclinical findings does not indicate how often negative or null experiments occurred.

Module 4: SLU-PP-332 Side Effects: What Studies Report

This is the module where the published record is thinnest, and that thinness is the finding. The verified studies were designed around efficacy and mechanism — exercise response and capacity (PMID 36988910), metabolic syndrome features (PMID 37739806), kidney mitochondrial and inflammatory markers (PMID 37717940), and cardiac function in heart failure models (PMID 37961903). None of these is a toxicology study, and this verified set contains no human safety data, no catalogue of treatment-emergent adverse events, and no long-term dosing safety report.

Receptor-level considerations raised elsewhere in the ERR literature

Because SLU-PP-332 engages all three ERR subtypes, questions about ERR biology outside muscle are relevant context rather than reported side effects. Researchers reported that ERRγ played a key role in vascular calcification through upregulation of BMP2 expression (PMID 26404484), and a separate study reported that the ERRγ-targeting compound DN200434 inhibited vascular smooth muscle cell proliferation and prevented neointima formation in mice after carotid artery ligation (PMID 36168774). These reports concern different molecules and, in the DN200434 case, modulation in a different direction; they do not describe adverse events caused by SLU-PP-332. They do show that ERR signalling has documented roles in vascular tissue that the SLU-PP-332 efficacy studies did not evaluate.

Screening context is similar: the Tox21 compound-library analysis identified ERRα agonists among screened chemicals as part of toxicological profiling efforts (PMID 29216352), which indicates ERRα activation is treated as a biological activity worth monitoring in screening programmes — not that any particular effect was observed with this compound.

Limits of the evidence in Module 4

• Absence of reported adverse events in efficacy studies is not the same as demonstrated safety.
• No verified study reported human tolerability, dose-limiting toxicity, drug interactions, or effects in pregnancy.
• Receptor-level findings in vascular tissue (PMID 26404484) raise open questions rather than answer them.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetic characterisation is limited in this verified set, and what exists is mostly indirect. The clearest signal comes from medicinal chemistry follow-up: researchers described SLU-PP-915 specifically as an orally active ERR agonist that enhanced aerobic exercise capacity (PMID 41421047). The emphasis on oral activity as a distinguishing feature of a newer analog indicates that improving drug-like properties within this chemical series was an explicit research objective, which is how such series usually progress.

Beyond that, the verified literature reports administration in rodent models without abstract-level PK parameters: no half-life, clearance, bioavailability percentage, or plasma exposure values appear in the sources listed here for SLU-PP-332 itself. Studies in the exercise (PMID 36988910), metabolic syndrome (PMID 37739806), and cardiac (PMID 37961903) settings were framed around pharmacodynamic endpoints. Readers wanting exact administration schedules should consult the primary methods sections of those papers directly, since regimen details are study-specific and not summarised accurately by secondhand descriptions.

Limits of the evidence in Module 5

• No human PK data exist in this verified literature.
• Rodent PK does not translate directly to humans, and species differences in nuclear-receptor pharmacology are common.
• Analog properties (for example, oral activity of SLU-PP-915) do not describe SLU-PP-332.

Module 6: Regulatory Status

Approved products

There is no approved medicine that is an ERR agonist. SLU-PP-332 has no marketing authorisation in the United States, the European Union, or any other jurisdiction known to this literature, and it appears in the record exclusively as an investigational research tool used in animal and cell studies (PMID 36988910, PMID 37739806).

Research-use-only status

Material distributed under this name is typically labelled "for research use only, not for human consumption." That label is a legal and commercial classification, not a quality certification: it signals that the substance has not been evaluated as a medicine and that no regulator has reviewed its identity, purity, or safety for human exposure. RUO materials are not manufactured under the standards applied to human pharmaceuticals.

Compounding

In the United States, compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may generally compound using bulk drug substances that are components of an FDA-approved drug, that appear in an applicable USP or NF monograph, or that appear on the relevant FDA bulk drug substances lists. SLU-PP-332 is not the active ingredient of an approved drug and does not have an applicable monograph in that framework, so it does not meet those criteria. Separately, it is not a dietary ingredient and is not lawfully marketed as a dietary supplement.

Sport and employment testing

The verified literature reviewed here does not address anti-doping classification, workplace testing, or military policy for SLU-PP-332 or other ERR agonists, so no statement about those frameworks is made on this page.

This section describes publicly stated regulatory frameworks for educational purposes and is not legal advice.

Limits of the evidence in Module 6

• Regulatory frameworks change; status described here reflects general rules rather than a current legal determination.
• Research-use-only labelling says nothing about what a given sample actually contains.
• No verified paper evaluated commercially distributed material.

What the Studies Did Not Test

Closing out the course, the clearest summary of SLU-PP-332 is a list of unanswered questions:

1. Humans. No clinical trial of SLU-PP-332 appears in this verified literature — no phase 1 safety study, no dose-ranging, no efficacy trial.
2. Body composition or performance in people. Exercise-capacity findings were animal endpoints (PMID 36988910, PMID 41421047), not human training or physique outcomes.
3. Long-term exposure. The verified studies did not report chronic multi-month or lifetime dosing safety.
4. Vascular consequences of pan-ERR activation. ERRγ has a documented role in vascular calcification via BMP2 (PMID 26404484), and the efficacy studies did not assess this endpoint.
5. Interactions. No verified study reported interactions with medicines, including drugs used in diabetes, heart failure, or kidney disease.
6. Special populations. Pregnancy, lactation, paediatric, and older human populations were not studied; the aging work was conducted in mouse kidney tissue (PMID 37717940).
7. Comparative effectiveness. No verified study compared SLU-PP-332 with exercise training or with established therapies for the conditions modelled (PMID 37961903).

Understanding a compound at this stage means holding two facts together: the preclinical mechanism is coherent and the animal findings were reported in reputable journals, and simultaneously the human evidence base is empty. Both statements are accurate, and neither cancels the other. Anyone weighing health decisions around this topic should do so with a licensed physician who can review the primary literature in context.

References

• Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (ACS Chemical Biology, 2023)
• A Synthetic ERR Agonist Alleviates Metabolic Syndrome (The Journal of Pharmacology and Experimental Therapeutics, 2024)
• Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney (The American Journal of Pathology, 2023)
• Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function (Circulation, 2024)
• Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study (Frontiers in Physiology, 2025)
• An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (The Journal of Pharmacology and Experimental Therapeutics, 2026)
• Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity (The Journal of Biological Chemistry, 2010)
• ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease (Autophagy, 2026)
• Identification of Estrogen-Related Receptor α Agonists in the Tox21 Compound Library (Endocrinology, 2018)
• Estrogen-Related Receptor γ Plays a Key Role in Vascular Calcification Through the Upregulation of BMP2 Expression (Arteriosclerosis, Thrombosis, and Vascular Biology, 2015)
• DN200434 Inhibits Vascular Smooth Muscle Cell Proliferation and Prevents Neointima Formation in Mice after Carotid Artery Ligation (Endocrinology and Metabolism, 2022)
• FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity (Journal of the American Society of Nephrology, 2018)